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Abstract
Purpose The purpose of this study was to evaluate longitudinal changes in brain gray matter density (GMD) before and after 
adjuvant chemotherapy in older women with breast cancer.
Methods We recruited 16 women aged ≥ 60 years with stage I–III breast cancers receiving adjuvant chemotherapy (CT) and 
15 age- and sex-matched healthy controls (HC). The CT group underwent brain MRI and the NIH Toolbox for Cognition 
testing prior to adjuvant chemotherapy (time point 1, TP1) and within 1 month after chemotherapy (time point 2, TP2). The 
HC group underwent the same assessments at matched intervals. GMD was evaluated with the voxel-based morphometry.
Results The mean age was 67 years in the CT group and 68.5 years in the HC group. There was significant GMD reduction 
within the chemotherapy group from TP1 to TP2. Compared to the HC group, the CT group displayed statistically signifi-
cantly greater GMD reductions from TP1 to TP2 in the brain regions involving the left anterior cingulate gyrus, right insula, 
and left middle temporal gyrus (pFWE(family-wise error)-corrected < 0.05). The baseline GMD in left insula was positively correlated 
with the baseline list-sorting working memory score in the HC group (pFWE-corrected < 0.05). No correlation was observed for 
the changes in GMD with the changes in cognitive testing scores from TP1 to TP2 (pFWE-corrected < 0.05).
Conclusions Our findings indicate that GMD reductions were associated with adjuvant chemotherapy in older women with 
breast cancer. Future studies are needed to understand the clinical significance of the neuroimaging findings. This study is 
registered on ClinicalTrials.gov (NCT01992432).
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Background
Patients who are receiving adjuvant chemotherapy for 
breast cancer have reported cognitive changes associated 
with receipt of cancer therapy [1]. However, the biologic 
basis for the cognitive issues is poorly understood. Prior 
studies in women with breast cancer have observed brain 
structural alterations with exposure to chemotherapy [2, 
3]. Few studies have focused on older women over 60 years 
of age who represent almost half of the new breast cancers 
diagnosed in the United States [4].
Neuroimaging studies have observed a decrease in gray 
matter density (GMD) and working memory function in 
younger patients with breast cancer with exposure to 
chemotherapy at mean age of 46.3 (SD = 6.1) years to 52.9 
(SD = 8.6) years [5–7]. Longitudinal studies have shown 
acutely reduced GMD 1 month after treatment in younger 
patients with breast cancer with mean ages at early 50 
years of age [6, 8]. However, none of these previous stud-
ies has specifically focused on older women with breast 
cancer. Moreover, there is a lack of assessment of neural 
correlates in older women with breast cancer who have had 
a history of exposure to chemotherapy.
In order to access the potential adverse impact of cancer 
treatments on brain structure and function in older patients 
receiving adjuvant chemotherapy, we performed a pilot 
study to evaluate longitudinal changes in GMD utilizing 
brain MRI scans. We hypothesized that GMD would be 
reduced in older women with breast cancer from pre- to 
post-adjuvant chemotherapy and the changes in GMD 
may be associated with a detrimental effect on cognitive 
performance.
Materials and methods
Participants
This was a longitudinal study of breast cancer patients 
scheduled to receive adjuvant chemotherapy and age-/sex-
matched healthy controls. The details of the study have been 
reported previously [9]. The eligibility criteria for patients 
with breast cancer were the following: diagnosis of stage 
I–III breast cancer, age 60 years and older, scheduled to 
receive adjuvant chemotherapy. The patients were excluded 
if they had metastatic disease or contraindications for brain 
MRI scan such as cardiac pacemaker, orbital metal implants 
or claustrophobia. Age- and sex-matched healthy controls 
with no cancer history or prior exposures to chemotherapy 
were recruited from the community through advertisement 
in local newspapers, patients’ referral of friends and family, 
and health fairs.
This research protocol was approved by the Institutional 
Review Board at City of Hope National Medical Center. 
Informed consent was obtained from all study participants.
Study measures including brain MRI scans and NIH Tool-
box for Cognition testing were completed both upon enroll-
ment at baseline (time point 1, TP1) and within 1 month 
following the completion of chemotherapy (time point 2, 
TP2). Healthy controls underwent the same assessments at 
matched intervals as the chemotherapy group.
Brain MRI acquisition
All participants underwent brain MRI scans at both time 
points on the same 3T Verio Siemens scanner (Siemens, 
Erlangen, Germany). The details of brain MRI imaging 
protocol have been described previously [9]. Briefly, both 
sagittal and axial T1-weighted three-dimensional (3D) mag-
netization prepared rapid gradient echo (MPRAGE) imaging 
data were acquired. A 3D fluid-attenuated inversion recovery 
(FLAIR) sequence was obtained to rule out incidental brain 
pathology.
Neuroimaging analysis
GMD was evaluated with the voxel-based morphometry 
(VBM) approach using the Diffeomorphic Anatomical 
Registration Through Exponentiated Lie Algebra (DAR-
TEL) Toolbox in the Statistical Parametric Mapping soft-
ware version 12 (SPM 12) (Wellcome Trust Centre for 
Neuroimaging, London, UK). It was performed using the 
following steps: (1) segmenting each T1 weighted image 
to generate the tissue (gray matter, white matter, and cer-
ebrospinal fluid) probability maps; (2) using DARTEL tool 
to improve the inter-subject alignment [10]; (3) spatially 
normalizing the gray matter probability maps into Montreal 
Neurological Institute (MNI) space [11] and smoothing 
(FHWM = 10 mm). The gray matter probability maps com-
puted from axial and sagittal T1 images for each scan were 
averaged after spatially normalized and smoothed for the 
group level statistical analysis. All T1 images are manually 
adjusted to reset the origin at the anterior commissural level 
and to set the posterior commissural level for the second axis 
of the coordinate system.
NIH toolbox for cognition testing
All study participants were administered a neuropsycho-
logical testing battery using the NIH Toolbox for Cognition 
[12]. Using normative data from a large national standardi-
zation sample as reference, the NIH Toolbox for Cognition 
employed measures to evaluate several subdomains such as 
365Breast Cancer Research and Treatment (2018) 172:363–370 
1 3
working memory, attention, executive function, processing 
speed, episodic memory, and language. It took approxi-
mately 30 min to perform this battery which generated a 
total of 10 scores consisting of 3 composite scores and 7 
individual scores.
Statistics analysis
The group differences in frequency distributions of base-
line demographic characteristics of the participants were 
assessed using Fisher’s exact tests. The group differences in 
the means of baseline age were assessed using a two-sample 
student t test. We considered a two-sided p value less than 
0.05 as statistically significant.
The GMD changes between two points in the healthy con-
trol (HC) and the chemotherapy (CT) groups, as well as the 
group difference in the GMD changes, were assessed using 
a mixed-design repeated measurement two-way Analysis of 
Variance (ANOVA) model in SPM12. The model included 
the group factor (HC and CT), the time factor (TP1 and 
TP2), and the subject factor that was used to account for the 
subject effect in repeated measurements. The analysis was 
implemented using the flexible factorial design in SPM12. 
We presented data for the summary of all significant clusters 
(pcorrected < 0.05) identified in voxel-wise ANOVA analysis of 
GMD. It includes cluster extent, cluster level p values, MNI 
coordinates, family-wise error rate corrected voxel level p 
value (pFWE-corrected), and anatomical regions of the cluster 
peaks. Local peaks in the clusters were included if the voxel 
level pFWE-corrected values were smaller than 0.05.
We performed voxel-wise regression analysis to explore 
potential linear correlations between baseline GMD and 
testing scores from the NIH Toolbox for Cognition in the 
brain regions where the CT group displayed statistically 
significant greater GMD reduction than the HC group. We 
also explored potential linear correlations in the CT group 
between GMD change and the changes in the neuropsycho-
logical testing scores before and after chemotherapy, using 
the same type of analysis. We used the baseline GMD as the 
independent variable and the baseline testing scores from the 
NIH Toolbox for Cognition as the regressor. When explor-
ing potential linear correlations between two change scores, 
these baseline measurements were changed to their corre-
sponding change scores between TP1 and TP2. The total 
intracranial volume (ICV) and the age of the subjects were 
used as covariates in all analysis to control for the effects of 
these two variables on GMD. The ICV was computed by 
summing the probabilities of gray matter, white matter and 
cerebrospinal fluid. The results were visualized using the 
xjView tool (http://www.alive learn .net/xjvie w). The statisti-
cal significance-based region of interest (ROI) was identified 
according to the family-wise error rate adjusted voxel level p 
value of the cluster peaks (pFWE-corrected ≤ 0.05). Unadjusted 
p value threshold (p ≤ 0.001) was used for building clusters.
Results
Characteristics of participants
Table 1 shows the characteristics of participants enrolled 
in this analysis. Sixteen female patients with breast cancer 
(mean age 67 years, range 60–82 years) and 15 age-matched 
healthy controls (mean age: 68.5 years, range 60–78 years) 
completed study measures for both time points. There was 
no significant difference in age (t test p = 0.37) or educa-
tion (Fisher’s exact test p = 0.58) between the CT group and 
the HC group. The CT group included 69% white females 
and 31% black females, whereas HC group consisted of 
Table 1  Demographic/disease/treatment information of the study par-
ticipants
TC docetaxel and cyclophosphamide, TCHP docetaxel, carboplatin, 
trastuzumab, pertuzumab, TCyHP docetaxel, cyclophosphamide, 
trastuzumab, pertuzumab, ddAC followed by paclitaxel dose-dense 
adriamycin cyclophosphamide followed by paclitaxel, TAC docetaxel, 
doxorubicin, and cyclophosphamide
Variable Chemotherapy (CT) Healthy control (HC)
No. of participants 16 15
Age (years)
 Mean 67.0 68.5
 SD 5.39 5.69
Range 60–82 60–78
Race
 White 11 (69%) 15 (100.0%)
 Black 5 (31%) 0 (0.0%)
Education
 High school 4 (25.0%) 1 (6.7%)
 Some college 8 (50.0%) 8 (53.3%)
 College degree 3 (18.8%) 4 (26.7%)
 Post college 1 (6.3%) 2 (13.3%)
Stage
 I 5 (31.3%) N/A
 II 8 (50.0%) N/A
 III 3 (18.8%) N/A
Regimen
 TC 7 (43.8%) N/A
 TCHP 1 (6.3%) N/A
 Paclitaxel/trastuzumab 4 (25%) N/A
 TCyHP 1 (6.3%) N/A
 Carboplatin/paclitaxel 1 (6.3%) N/A
 ddAC followed by 
paclitaxel
1 (6.3%) N/A
 TAC 1 (6.3%) N/A
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all white females (Fisher’s exact test p = 0.04). CT group 
included 31% patients with stage I, 50% patients with stage 
II and 19% patients with stage III breast cancer. Forty-four 
percent patients received docetaxel and cyclophosphamide; 
25% patients received paclitaxel and trastuzumab; and the 
remaining 32% (5 patients) received 5 different chemother-
apy regimens.
GMD measurement
Baseline GMD
There were no brain regions showing statistically signifi-
cant between-group differences in GMD cross-sectionally 
at baseline after correction for the multiple comparisons 
(pcorrected > 0.05).
Within‑group GMD changes between TP1 and TP2
There were substantial GMD reductions in the CT group 
from TP1 to TP2 (pcorrected < 0.05) (Table 2). The affected 
brain regions included bilateral inferior frontal gyri, bilat-
eral insula, left anterior cingulate, left inferior frontal gyrus 
(BA 47), left middle temporal gyrus, left caudate and right 
middle frontal gyrus (Table 2). In the HC group from TP1 
to TP2, no gray matter density reductions were statistically 
significant (pFWE-corrected > 0.05).
Between‑group comparison of GMD changes
There were 9 clusters where the CT group displayed sig-
nificantly greater reductions than the HC group in GMD 
at pcorrected < 0.05 (Table 2; Fig. 1). Some clusters were 
distributed in a bilateral pattern in the brain. The peaks of 
the clusters were located in left anterior cingulate, bilateral 
insula, left middle temporal gyrus, left parahippocampal 
Table 2  Regional gray matter density alterations
TP1 time point 1, TP2 time point 2, L left, R right, FWE family-wise error
a MNI coordinates of the cluster peaks and those local peaks within each cluster whose voxel-level family error rate corrected p values smaller 
than 0.001 were listed in the table
b The anatomical regions of the peaks were indicated according to the Talairach Daemon atlas
MNI coordinates (x y z)a Cluster extent (k) Cluster-level Voxel-level T Region (selected local  maximab)
pcorrected pFWE-corrected
Within group
 Chemotherapy: TP2 < TP1
  − 43.5 24 − 1.5 109,650 < 0.0001 0.0003 8.86 L Inferior Frontal Gyrus
  37.5 24 9 109,650 < 0.0001 0.0097 7.14 R Inferior Frontal Gyrus
  39 − 19.5 18 109,650 < 0.0001 0.0006 8.47 R Insula
  − 39 − 15 16.5 109,650 < 0.0001 0.0008 8.3 L Insula
  − 7.5 34.5 27 109,650 < 0.0001 0.0009 8.28 L Anterior Cingulate
  − 37.5 18 − 3 109,650 < 0.0001 0.0024 7.78 L Inferior Frontal Gyrus (BA 47)
  − 48 − 31.5 − 4.5 109,650 < 0.0001 0.0047 7.48 L Middle Temporal Gyrus
  − 7.5 12 0 2381 < 0.0001 0.1788 5.77 L Caudate (Caudate Head)
  31.5 − 4.5 49.5 514 0.0012 0.2267 5.65 R Middle Frontal Gyrus
Between-group
 Reductions in chemother-
apy > healthy control
  − 7.5 34.5 27 1591 < 0.0001 0.015 6.94 L Anterior Cingulate
  39 − 19.5 18 3571 < 0.0001 0.027 6.67 R Insula
  − 39 − 15 16.5 4315 < 0.0001 0.0847 6.14 L Insula
  − 64.5 − 25.5 − 7.5 2785 < 0.0001 0.0448 6.43 L Middle Temporal Gyrus
  − 19.5 − 46.5 − 9 9242 < 0.0001 0.0613 6.29 L Parahippocampal Gyrus
  24 − 63 − 14 6444 < 0.0001 0.036 5.95 R Fusiform Gyrus
  43.5 43.5 12 462 0.0025 0.4189 5.31 R Inferior Frontal Gyrus (BA 46)
  40.5 − 45 36 930 < 0.0001 0.6784 4.97 R Supramarginal Gyrus (BA 40)
  58.5 − 22.5 − 7.5 508 0.0013 0.7433 4.89 R Middle Temporal Gyrus (BA 21)
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gyrus, right fusiform gyrus, right inferior frontal gyrus (BA 
46), right supramarginal gyrus (BA 40), and right middle 
temporal gyrus (BA 21). In addition, three of the clusters 
located in left anterior cingulate gyrus, right insula, and left 
middle temporal gyrus also reached statistical significance 
at the voxel level (pFWE-corrected < 0.05).
Neuropsychological testing
The summary of all NIH Toolbox testing scores for this 
study has been reported previously [9]. Briefly, there were 
no significant differences between the CT group and the HC 
group in the NIH Toolbox for Cognition testing scores at 
TP1 or at TP2, or the changes in the testing scores from TP1 
to TP2 (p values > 0.05).
Correlative analysis between GMD 
and neuropsychological testing scores
Our voxel-wise linear regression analysis detected a 240-
voxel size cluster (Fig. 2a) where the baseline GMD was 
statistically significantly correlated with the list-sorting 
working memory score (pFWE-corrected < 0.05). The cluster 
peak of the t-statistic was located in the left insula at the 
MNI coordinates (− 30 − 26 20). Furthermore, correla-
tive analysis of the baseline GMD at the cluster peak and 
the list-sorting working memory score confirmed a strong 
positive correlation in the HC group (correlation coeffi-
cient = 0.76, p = 0.0009, Fig. 2b). There was also a trend of 
correlation in the CT group with correlation coefficient of 
0.41, although it was not statistically significant (Fig. 2c, 
p = 0.12). None of the other baseline NIH Toolbox cogni-
tive testing scores was significantly correlated with baseline 
GMD (pFWE-corrected > 0.05).
Voxel-wise regression analysis did not detect any sig-
nificant linear correlation between GMD changes and the 
changes in all the neuropsychological testing scores in the 
CT group (pFWE-corrected > 0.05).
Discussion
Our study showed acute GMD reduction in older patients 
with breast cancer from pre- to post- exposure to adjuvant 
chemotherapy. To the best of our knowledge, the present 
study is one of the few longitudinal studies focusing on the 
potential adverse impact of adjuvant chemotherapy on brain 
structure and function in older patients.
Our study findings of GMD reduction in older patients 
with breast cancer who had received chemotherapy are con-
sistent with findings of prior studies in younger patients [13]. 
Furthermore, the affected brain regions in our study were in 
general agreement with prior neuroimaging literature [14]. 
Prior longitudinal studies with similar study design but in a 
younger patient population showed acute reduction in fron-
tal temporal GMD at 1 month after chemotherapy and the 
frontal temporal lobes were the brain regions most sensitive 
to the chemotherapy insult [5–7]. Our study with a focus on 
older adults with cancer has also identified brain regions in 
the frontal temporal lobes that displayed significant GMD 
reduction including the inferior frontal gyrus and middle 
frontal gyrus in the chemotherapy-treated group, similar to 
the affected brain regions identified in the younger popula-
tion. In addition, we have observed greater GMD reduc-
tions in the chemotherapy group as compared to the healthy 
control group. The involved brain regions included the left 
anterior cingulate gyrus, bilateral insula, bilateral middle 
temporal gyri, and left parahippocampal gyrus. Most  of the 
invovled regions have also been reported previously in other 
studies with similar longitudinal design in patients with 
breast cancer with exposure to chemotherapy [6, 8]. Our 
study identified the frontal temporal brain regions that are 
known to be critical for executive function such as working 
memory [7, 15, 16].
In contrast to the prior literature, we also identified GMD 
reductions in the brain regions that were not previously 
reported. For example, we identified statistically significant 
GMD reductions in both the left and the right insular cor-
tex, while a study by Lepage and colleagues showed GMD 
reduction in the left insula only [8]. In addition, our study 
detected a greater spatial extent of GMD reduction (mani-
fested by larger cluster sizes) in the affected brain regions 
Fig. 1  Highlighted brain regions indicating greater gray matter den-
sity (GMD) reduction in the chemotherapy group than in the healthy 
control group
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than what has been reported by the previous research [6–8]. 
It is intriguing that our study results have indicated more 
extensive GMD changes in terms of larger and additional 
affected brain regions. It is conceivable that our study cohort 
of older women with breast cancer might be more suscepti-
ble to treatment related brain structural alterations. However, 
it is also possible that a number of other possibilities such 
as difference in chemotherapy regimens or pre-existing co-
morbidities could have contributed to this finding. Further 
studies with larger sample size are needed to understand 
what risk factors contribute to more extensive acute GMD 
reduction in older patients with breast cancer receiving adju-
vant chemotherapy.
Although we observed GMD reduction, we did not find 
a statistically significant positive linear correlation between 
the GMD reduction and the changes in the neuropsychologi-
cal testing scores. Other studies in contrast have identified 
correlation between GMD reduction and neuropsychological 
testing scores in patients treated with chemotherapy. In par-
ticular, a study by Lepage and colleagues observed signifi-
cant correlation between gray matter reduction in the left 
insular cortex and processing speed in the chemotherapy-
treated group [8]. Another study showed decreased activa-
tion in the insula during verbal memory recall testing in 
patients with breast cancer with exposure to chemotherapy 
[17]. There are several possible reasons why we did not 
identify changes in neuropsychological testing. The patients 
may be able to compensate their brain function to keep their 
cognitive performance within the norm even though they 
have decreased GMD [18, 19]. Prior research has shown that 
patients may enhance their cognitive function by recruit-
ing and activating additional neurocircuitry during a high-
memory task load before chemotherapy compared to healthy 
controls [20]. We speculated that the chemotherapy-treated 
older patients in our study cohort may have utilized similar 
compensatory mechanisms; however, our pilot study cannot 
Fig. 2  Correlation between baseline gray matter density (GMD) in 
left insula and list-sorting working memory scores. a Brain region in 
left insula at MNI coordinates (− 30 − 26 20) where baseline GMD 
in the healthy control group (HC) was significantly correlated with 
list-sorting working memory score. b Significant correlation between 
baseline GMD in left insula and list-sorting working memory score 
in the HC group (correlation coefficient = 0.76, p = 0.0009). c Corre-
lation between baseline GMD in left insular and list-sorting working 
memory score in the chemotherapy group (CT) (correlation coeffi-
cient = 0.41, p = 0.12)
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ascertain the exact reason for our lack of decline in neu-
ropsychological testing. We acknowledge that our modest 
sample size might not have been adequate enough to identify 
small differences in cognitive performance.
It is noteworthy that among our patients, the baseline 
GMD in left insula was positively correlated with the base-
line list-sorting working memory score, though the cor-
relation reached statistical significance only in the healthy 
control group. Our study result provides some credence to 
our hypothesis that there is an association between neural 
correlates and neuropsychological testing. Furthermore, our 
study result of baseline GMD being correlated with cog-
nitive testing was consistent with the previous reports [8, 
17, 18]. However, we hypothesize that larger studies will 
be needed to identify significant correlation between GMD 
and neuropsychological testing scores in the chemotherapy 
group.
There were several limitations in this study. First, our 
study participants were followed longitudinally for a 
short time course from pre- to post-chemotherapy. Hence, 
we could not comment on long-term or delayed effect of 
chemotherapy on brain structure. Second, the patients in 
our study received a variety of different chemotherapy regi-
mens, which may have caused inhomogeneous changes in 
GMD. We did not have a sufficient sample size to identify 
the potentially different effects of chemotherapy regimens. 
Third, this study did not include a breast cancer control 
group with no history of chemotherapy, and we could not 
ascertain definitively whether the findings were attributable 
to chemotherapy or to a breast cancer diagnosis in general. 
Lastly, as mentioned above, our sample size was modest, 
which may have limited the ability to identify small changes 
in neuropsychological testing or GMD.
Despite the limitations, there were strengths in this study. 
The prospective longitudinal design of our study allowed 
assessment of brain structural alteration over time. With a 
focus on older adults with cancer, we contributed to fill-
ing the knowledge gap regarding potential neural correlates 
of cognition in the older patients with cancer undergoing 
systemic treatment. This pilot study has served to generate 
hypotheses for future larger studies to help unravel the bio-
logical mechanism responsible for cancer-related cognitive 
impairment.
Conclusion
Our findings indicate that GMD reductions were associated 
with adjuvant chemotherapy in older women with breast 
cancer. Future larger studies with greater statistical power 
and independent replication are needed to understand the 
clinical significance of these neuroimaging findings.
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